苯并二氢呋喃-2-羧酸 | 1914-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 苯并二氢呋喃-2-羧酸
• 中文别名: 2,3-二氢-1-苯并呋喃-2-羧酸
• 英文名称: 2,3-dihydro-1-benzofuran-2-carboxylic acid
• 英文别名: 2,3-dihydrobenzofuran-2-carboxylic acid；(+/-)-2,3-Dihydro-benzofuran-2-carbonsaeure；2,3-dihydro-2-benzofurancarboxylic acid
• CAS: 1914-60-9
• 化学式: C₉H₈O₃
• mdl: MFCD03086168
• 分子量: 164.161
• InChiKey: WEVFUSSJCGAVOH-UHFFFAOYSA-N

物化性质

• 熔点：
  116-118
• 沸点：
  340.5±31.0 °C(Predicted)
• 密度：
  1.347±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S37/39
• 海关编码：
  2932999099
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Name:	2 3-Dihydro-1-benzofuran-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	1914-60-9

Section 1 - Chemical Product MSDS Name:2 3-Dihydro-1-benzofuran-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1914-60-9	2,3-Dihydro-1-benzofuran-2-carboxylic	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1914-60-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 116 - 118 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8O3
Molecular Weight: 164.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1914-60-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dihydro-1-benzofuran-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 1914-60-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1914-60-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1914-60-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苯并二氢呋喃-2-羧酸 生成 2,3-dihydrobenzofuran-2(R)-carboxylic acid
  参考文献：
  名称：

  Fredga; Vazquez de Castro y Sarmiento, Arkiv foer Kemi, 1954, vol. 7, p. 387,388, 389

  摘要：

  DOI：
• 作为产物：
  描述：

  2-烯丙基酚 在 sodium hypochlorite 、 2,2,6,6-四甲基哌啶氧化物 、 2,2,2-三氟苯乙酮 、 双氧水 、 碳酸氢钠 、 potassium bromide 作用下， 以 四氢呋喃 、 水 、 乙腈 、 叔丁醇 为溶剂， 反应 22.0h， 生成 苯并二氢呋喃-2-羧酸
  参考文献：
  名称：

  烯丙基苯酚的氧化环化反应绿色有机催化合成二氢苯并呋喃

  摘要：

  作为专题“现代合成中的环化策略”的一部分发布 抽象的 提出了一种绿色廉价的方案，用于通过邻烯丙基苯酚的有机催化氧化合成二氢苯并呋喃。使用2,2,2-三氟苯乙酮和H 2 O 2作为氧化系统，导致了一种非常有用的合成方法，其中各种取代的邻烯丙基苯酚均以高收率环化。 提出了一种绿色廉价的方案，用于通过邻烯丙基苯酚的有机催化氧化合成二氢苯并呋喃。使用2,2,2-三氟苯乙酮和H 2 O 2作为氧化系统，导致了一种非常有用的合成方法，其中各种取代的邻烯丙基苯酚均以高收率环化。

  DOI：

  10.1055/s-0036-1588998

文献信息

• [EN] INDAZOLE DERIVATIVES WHICH INTERACT WITH THE G-PROTEIN COUPLED RECEPTOR FAMILY<br/>[FR] DERIVES D'INDAZOLE D'INTERACTION AVEC LA FAMILLE DES RECEPTEURS COUPLES A LA PROTEINE G
  申请人：BIOFOCUS DISCOVERY LTD

  公开号：WO2005056532A1

  公开（公告）日：2005-06-23

  Compounds of the general formula: (I) wherein Y, R and R’ are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament against BRS-3 receptor-related disorders.

  公式（I）中的Y、R和R'如说明书所述。进一步包括包含这些化合物的药物组合物，它们的制备过程，以及这些化合物用于制备治疗BRS-3受体相关疾病的药物的应用。
• Substituted Pyrrolidines and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180099931A1

  公开（公告）日：2018-04-12

  The invention discloses compounds of Formula (I) wherein R 1 , R 2 , R 2A , R 3 , R 3A , R 4 , R 4A , and R 5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明公开了式（I）的化合物 其中R 1 ，R 2 ，R 2A ，R 3 ，R 3A ，R 4 ，R 4A 和R 5 如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• [EN] N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES<br/>[FR] DÉRIVÉS DE N-(4-(OXAZOL-5-YL) PHÉNYL)CHROMANE-3-CARBOXAMIDE ET COMPOSÉS APPARENTÉS EN TANT QUE STIMULATEURS DE LA PRODUCTION DE CELLULES PRÉCURSEURS RÉTINIENNES POUR LE TRAITEMENT DE MALADIES NEURORÉTINIENNES
  申请人：ENDOGENA THERAPEUTICS INC

  公开号：WO2020140050A1

  公开（公告）日：2020-07-02

  New compounds and to a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, comprising administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a is selected from the group consisting of a 5-oxazolyl, a pyridine-4-yl, a triazolyl, a oxadiazolyl, a imidazolyl and a 2-methyloxazol-5-yl residue, R1, and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) wherein, II*II denotes the point of attachment to the remainder of the molecule, and R2, R3, R4, R5, R2 I, R3 I, R4 I, R5 I, R2 II, R3 II R4 II, R5 II, R2 III, R3 III, R4 III, R5 III, R2 IV, R3 IV, R4 IV, R5 IV, R2 V, R3 V, R4 V, R5 V , R2 VI, R3 VI, R4 VI, R5 VI,R2 VII, R3 VII, R4 VII, R5 VII, are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, 2,2,2-trifluoromethyl and difluoromethoxy.

  新化合物及治疗导致光感受器丧失或外视网膜退化的视网膜疾病的方法，包括给予式(I)的化合物或其药学上可接受的盐、消旋混合物、相应对映体或如适用的话，相应的二对映体，其中：A选自由5-噁唑基、吡啶-4-基、三唑基、噁二唑基、咪唑基和2-甲氧基噁唑-5-基残基的群组，R1和R12独立选自氢、氟、氯、甲氧基、三氟甲基、甲基和二氟甲氧基的群组，B选自式(II)、(III)、(IV)、(V)、(VI)、(VII)、(VIII)和(IX)的残基的群组，其中，II*II表示与分子其余部分的连接点，R2、R3、R4、R5、R2 I、R3 I、R4 I、R5 I、R2 II、R3 II、R4 II、R5 II、R2 III、R3 III、R4 III、R5 III、R2 IV、R3 IV、R4 IV、R5 IV、R2 V、R3 V、R4 V、R5 V、R2 VI、R3 VI、R4 VI、R5 VI、R2 VII、R3 VII、R4 VII、R5 VII独立选自氢、具有1至3个碳原子的直链或支链烷基、氟、氯、溴、甲氧基、乙氧基、丙氧基、2,2,2-三氟甲基和二氟甲氧基的群组。
• <i>meta</i> C–H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity
  作者：Luo-Yan Liu、Jennifer X. Qiao、Kap-Sun Yeung、William R. Ewing、Jin-Quan Yu

  DOI：10.1021/jacs.9b07887

  日期：2019.9.18

  report the first catalytic system that effectively performs meta C-H arylation of a variety of alkoxy aromatics including 2,3-dihydrobenzofuran and chromane with exclusive meta site-selectivity, thus reversing the conventional site selectivity governed by native electronic effects. The identification of an effective ligand and modified norbornene (NBE-CO2Me), as well as taking advantage of the statistics

  在不使用导向基团的情况下控制 CH 活化的位点选择性仍然是一个重大挑战。虽然由相互排斥的吡啶型配体调节的 Pd(II) 催化剂已被证明有利于芳烃相对富电子的碳中心，但逆转选择性以有利于相对缺电子位置的钯化作用是不可能的。在这里，我们报告了第一个催化系统，该系统有效地对包括 2,3-二氢苯并呋喃和色烷在内的各种烷氧基芳烃进行间位 CH 芳基化，具有独特的间位选择性，从而逆转了由天然电子效应控制的传统位点选择性。有效配体和改性降冰片烯 (NBE-CO2Me) 的鉴定，
• [EN] BORONIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE
  申请人：MERCK PATENT GMBH

  公开号：WO2020020858A1

  公开（公告）日：2020-01-30

  The present invention relates to α-amino boronic acid derivatives. These compounds are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.

  本发明涉及α-氨基硼酸衍生物。这些化合物对抑制免疫蛋白酶体(LMP7)的活性以及治疗和/或预防受免疫蛋白酶体活性影响的医疗状况，如炎症性和自身免疫疾病、神经退行性疾病、增殖性疾病和癌症，具有用处。